Last reviewed · How we verify
NCT02967757
In-market Utilisation of Liraglutide Used for Weight Management in Europe
trial testing liraglutide in Metabolism and Nutrition Disorder in 316 participants. Completed in 28 May 2019.
28 May 2019
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 316 |
| Start date | 22 December 2016 |
| Primary completion | 28 May 2019 |
| Estimated completion | 28 May 2019 |
| Sites | 19 locations across Italy, Germany |
Drugs / interventions tested
- liraglutide (liraglutide) — full drug profile →
Conditions studied
- Metabolism and Nutrition Disorder — all drugs for Metabolism and Nutrition Disorder →
- Obesity — all drugs for Obesity →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
Eligibility, any sex, with Metabolism and Nutrition Disorder or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02967757
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of liraglutide
Trials testing the same drug.
- NCT07244003 — Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control · Phase 4 · recruiting
- NCT05965908 — Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome · Phase 3 · completed
- NCT05681299 — Effects of GH and Lirglutide on AgRP · Phase 4 · recruiting
- NCT03292185 — A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec a · Phase 1 · completed
- NCT02964247 — LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. · Phase 3 · completed
Other recruiting trials for Metabolism and Nutrition Disorder
Currently open trials in the same condition.
- NCT05785221 — Energy Metabolism Profiles Over Weight-loss and Eating Responses · NA · active not recruiting
- NCT03669809 — The Biological Rhythm of Human Metabolite · recruiting
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02967757 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 20 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02967757.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing